

#### PRIOR AUTHORIZATION REQUEST FORM

#### EOC ID:

# Ferriprox (deferiprone)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. What diagnosis is this drug being prescribed for?		
☐ Transfusional iron overload ☐ Other		
Q2. Please indicate diagnosis and ICD code(s).		
Q3. How will Ferriprox be billed?		
☐ Pharmacy claim (drug to be billed as a PHARMACY benefit claim and dispensed by pharmacy directly to member) ☐ Pharmacy claim (drug to be billed as a PHARMACY benefit claim, but shipped direct to provider to be administered to this specific member)		
☐ MEDICAL claim (drug to be billed by PROVIDER as a MEDICAL benefit claim as an expense to the provider, and provider to supply drug to member)		
Q4. If drug is to be billed as a MEDICAL claim, what provide seeking reimbursement)? Provide Name and NPI.	der will be linked to the claim (i.e. w	ho is the billing entity
☐ Individual prescriber		
☐ Provider or specialty group		
☐ Facility		



### PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

## Ferriprox (deferiprone)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
Q5. Is the requested dose within the FDA approved dosing for Ferriprox?		
☐ Yes ☐ No		
Q6. Please provide patient's current weight and requested dosing regimen.		
Q7. Is patient 10 years of age or older?		
☐ Yes ☐ No		
Q8. Is prescribing physician a hematologist or oncologist?		
☐ Yes ☐ No		
Q9. Has patient experienced a therapeutic failure on Exjad	e?	
☐ Yes ☐ No		
Q10. If patient has not experienced a therapeutic failure on Exjade, does patient have an intolerance or contraindication to Exjade?		
☐ Yes (please explain) ☐ No		
Q11. Additional Comments		
Prescriber Signature	Date	

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.



# PRIOR AUTHORIZATION REQUEST FORM EOC ID:

## Ferriprox (deferiprone)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician:

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document